No article notes available at this time.
• Reinforces that despite newer targeted agents, doxorubicin and ifosfamide remain the backbone of treatment — useful context for trainees evaluating first-line regimen choices. • Highlights the shift toward subtype-specific therapy (eribulin, trabectedin, pazopanib, imatinib), which should inform how residents think about histology-driven treatment selection rather than treating soft tissue sarcoma as one disease. • Frames each new approval as incremental rather than transformative — useful for calibrating expectations when counseling patients on systemic therapy options.
No article notes available at this time.
• Reinforces that despite newer targeted agents, doxorubicin and ifosfamide remain the backbone of treatment — useful context for trainees evaluating first-line regimen choices. • Highlights the shift toward subtype-specific therapy (eribulin, trabectedin, pazopanib, imatinib), which should inform how residents think about histology-driven treatment selection rather than treating soft tissue sarcoma as one disease. • Frames each new approval as incremental rather than transformative — useful for calibrating expectations when counseling patients on systemic therapy options.